Literature DB >> 9639527

The evolution of B precursor leukemia in the Emu-ret mouse.

R Wasserman1, X X Zeng, R R Hardy.   

Abstract

Emu-ret mice carrying an RFP/RET fusion gene under the transcriptional control of the immunoglobulin heavy chain enhancer develop B lineage leukemias/lymphomas. We have characterized B-cell development in these mice before the onset of clinical disease to determine the steps involved in leukemogenesis. Flow cytometry reveals that the CD45R+CD43(+)CD24(+)BP-1(+) late pro-B-cell population is markedly expanded in the bone marrow of 3- to 5-week-old Emu-ret mice. Compared with late pro-B cells from transgene-negative mice, Emu-ret late pro-B cells have a limited capacity to differentiate in interleukin (IL)-7 and a higher incidence of VDJ rearrangements, but a similar cell cycle profile. In contrast, CD45R+CD43(+)CD24(+)BP-1(-) early pro-B cells from 3- to 5-week-old Emu-ret mice, which also express the RFP/RET transgene, differentiate in IL-7 similarly to their normal counterparts. Furthermore, early pro-B cells from Emu-ret and transgene-negative mice have an identical pattern of growth inhibition when exposed to interferons (IFNs)-alpha/beta and -gamma, whereas, pro-B-cell leukemia lines derived from Emu-ret mice are markedly less sensitive to growth inhibition by these IFNs. In 13-week-old well-appearing Emu-ret mice, late pro-B cells upregulate CYCLIN D1 expression and downregulate CASPASE-1 expression in a pattern that correlates with the emergence of B precursor cells in the peripheral blood and the loss of other B lineage subsets in the bone marrow. Taken together, these results suggest that the expression of the RFP/RET transgene initially prevents the normal elimination of late pro-B cells with nonproductive rearrangements. Secondary events that simultaneously disturb the normal transcriptional regulation of genes involved in the control of the cell cycle and apoptosis may allow for subsequent malignant transformation within the expanded late pro-B-cell population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639527

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Equal transcription rates of productively and nonproductively rearranged immunoglobulin mu heavy chain alleles in a pro-B cell line.

Authors:  Andrea B Eberle; Kai Herrmann; Hans-Martin Jäck; Oliver Mühlemann
Journal:  RNA       Date:  2009-04-10       Impact factor: 4.942

2.  Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.

Authors:  S Jo; J H Lee; J J Mattei; D M Barrett; P van den Elzen; S A Grupp; G S D Reid; A E Seif
Journal:  Leukemia       Date:  2017-09-19       Impact factor: 11.528

3.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Authors:  David M Barrett; Alix E Seif; Carmine Carpenito; David T Teachey; Jonathan D Fish; Carl H June; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

4.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 5.  Role of the BCR complex in B cell development, activation, and leukemic transformation.

Authors:  Susan R Rheingold; Valerie I Brown; Junjie Fang; Jenny M Kim; Stephan A Grupp
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.

Authors:  Alix E Seif; David M Barrett; Michael Milone; Valerie I Brown; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 7.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Authors:  David Barrett; Valerie I Brown; Stephan A Grupp; David T Teachey
Journal:  Paediatr Drugs       Date:  2012-10-01       Impact factor: 3.930

9.  CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Authors:  Elad Jacoby; Sang M Nguyen; Thomas J Fountaine; Kathryn Welp; Berkley Gryder; Haiying Qin; Yinmeng Yang; Christopher D Chien; Alix E Seif; Haiyan Lei; Young K Song; Javed Khan; Daniel W Lee; Crystal L Mackall; Rebecca A Gardner; Michael C Jensen; Jack F Shern; Terry J Fry
Journal:  Nat Commun       Date:  2016-07-27       Impact factor: 14.919

10.  Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses.

Authors:  M Fidanza; A E Seif; A DeMicco; N Rolf; S Jo; B Yin; Y Li; D M Barrett; J Duque-Afonso; M L Cleary; C H Bassing; S A Grupp; G S D Reid
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.